Qingyian Liu
Amgen (United States)(US)Université Bourgogne Franche-Comté(FR)
Publications by Year
Research Areas
Alzheimer's disease research and treatments, Coagulation, Bradykinin, Polyphosphates, and Angioedema, Computational Drug Discovery Methods, Ion Channels and Receptors, Cholinesterase and Neurodegenerative Diseases
Most-Cited Works
- → Discovery of Potent, Orally Available Vanilloid Receptor-1 Antagonists. Structure−Activity Relationship of N-Aryl Cinnamides(2004)102 cited
- → Discovery of TRPM8 Antagonist (S)-6-(((3-Fluoro-4-(trifluoromethoxy)phenyl)(3-fluoropyridin-2-yl)methyl)carbamoyl)nicotinic Acid (AMG 333), a Clinical Candidate for the Treatment of Migraine(2018)61 cited
- → The discovery of 2-anilinothiazolones as 11β-HSD1 inhibitors(2007)41 cited
- → Discovery of AM-6494: A Potent and Orally Efficacious β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor with in Vivo Selectivity over BACE2(2019)33 cited
- → Development of 2-aminooxazoline 3-azaxanthenes as orally efficacious β-secretase inhibitors for the potential treatment of Alzheimer’s disease(2015)30 cited
- → Further Studies with the 2-Amino-1,3-thiazol-4(5H)-one Class of 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors: Reducing Pregnane X Receptor Activity and Exploring Activity in a Monkey Pharmacodynamic Model(2008)28 cited
- → Potent Nonpeptide Antagonists of the Bradykinin B1 Receptor: Structure−Activity Relationship Studies with Novel Diaminochroman Carboxamides(2007)26 cited
- → Synthesis and evaluation of thiazole carboxamides as vanilloid receptor 1 (TRPV1) antagonists(2005)26 cited
- → N-Aryl-γ-lactams as integrin αvβ3 antagonists(2004)24 cited
- → Melanocortin subtype-4 receptor agonists containing a piperazine core with substituted aryl sulfonamides(2005)19 cited